Publication | Open Access
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
97
Citations
14
References
2024
Year
Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.
| Year | Citations | |
|---|---|---|
Page 1
Page 1